Surgery
Gastric Balloon Cost in 2026, and What the FDA Trial Actually Showed
Gastric balloon pricing swings widely between practices, and the number on its own tells you almost nothing. Two quotes that look far apart can cover completely different things, and the cheaper one is frequently the more expensive choice by the time you are finished.
There is also a development most pricing pages have not caught up to. The Allurion Balloon received FDA approval in February 2026, and the document behind that approval contains outcome data that differs substantially from the figures being used to market it. That data is public, and it is worth reading before you spend the money.
What we charge
Karas Weight Loss & Wellness quotes one all inclusive price for the Allurion program, given to you in writing at the consultation along with the list of what it covers.
We do not post a figure here. Balloon pricing in this market is moving quickly, promotional offers appear and disappear, and a number published on a web page tends to outlive its accuracy. What this page gives you instead is everything you need to evaluate any quote, including ours.
Balloons are not covered by insurance in almost all cases, so every price you encounter is a cash price.
What the price should include
A gastric balloon quote should account for four things: the device, the placement, the program that runs alongside it, and the exit. Ask about each one specifically, because that is where two similar looking quotes diverge.
For a swallowed balloon like the Allurion, there is no endoscopy and no anesthesia for placement, and there is no removal appointment at all, because the balloon empties on its own and passes naturally. That removes two facility charges and two anesthesia charges that an endoscopically placed balloon has to carry. It is the structural reason a swallowed balloon can be priced below an endoscopic one.
For an endoscopically placed balloon such as the Orbera, the price has to cover two endoscopic appointments with sedation, one to place and one to remove. If a quote for that type of balloon does not mention removal, ask, because it is the most commonly omitted line item in the category.
The nutrition and monitoring program is where quotes vary most, and it is also the part that does the most work. Ask how many months of support are included, how many visits, and who you actually see at them.
The Allurion balloon is now FDA approved, and the approval is specific
The FDA approved the Allurion Gastric Balloon System through the Premarket Approval pathway, PMA number P250023, with a decision date of February 20, 2026. Premarket Approval is the more rigorous of the two device pathways and requires clinical evidence of safety and effectiveness rather than a demonstration of similarity to an existing device.
The approved indication reads as short term limited weight loss in adults aged 22 to 65 with a BMI of at least 30 and no more than 40, who have failed at least one prior weight loss program.
Read that carefully, because it is narrower than most marketing suggests. If you are 21, or 66, or your BMI is 42, you are outside the approved indication.
The approval also defines the system in a way almost nothing written about it mentions. The FDA’s language is that the system “consists of up to two Allurion Balloons placed during a 10 month period.” A second balloon is placed roughly 24 weeks after the first, or two months after the first passes, whichever comes first.
Ask what a balloon quote actually covers
Placement is the smallest part of the program. Dr. Karas quotes the placement, the monitoring, the nutrition visits and the follow up as one written number at the consultation.
What the trial actually found
The pivotal study is AUDACITY, a prospective randomized open label trial. The analysis population was 527 adults, 264 assigned to the balloon plus a lifestyle program and 263 to the lifestyle program alone. Completion was not high: 397 participants reached week 24 and 367 completed the full 48 weeks.
At 48 weeks, mean total body weight loss was 6.87 percent in the balloon group and 3.09 percent in the lifestyle only group. Fifty eight percent of balloon participants achieved at least 5 percent total body weight loss, which cleared the trial’s first co-primary endpoint threshold of 50 percent.
The second co-primary endpoint was not met. It required the difference between the two groups to exceed a prespecified 3.0 percentage point margin under the trial’s primary statistical model, and the observed difference under that model was 3.05 percentage points with a p value of 0.1616, which did not reach significance. A secondary analysis method produced a larger difference of 3.77 points. FDA approved the device on the totality of the evidence rather than on both endpoints being met, which is a normal outcome and also a fact worth knowing.
Roughly a third of participants did not complete the study, which is common in weight loss trials and is a real limitation on how confidently anyone should read the average.
The figures you will see in marketing
Allurion’s own materials cite roughly 14 percent total body weight loss with one balloon cycle. That figure comes from real world commercial registry data collected across the company’s international markets, not from the randomized trial.
Registry data has a well understood problem: the people who stay in a registry and keep reporting their weight are not a random sample of the people who started. The ones who did poorly tend to stop answering. The trial exists precisely to correct for that, and the trial number is 6.87 percent.
I am pointing this out about a program this practice offers, because a patient deciding how to spend several thousand dollars deserves the number that came from the controlled study rather than the number that came from marketing.
The safety finding inside the two balloon protocol
The FDA’s safety summary contains a pattern worth knowing about before you agree to a second balloon.
Across the trial there were 21 serious adverse events, 18 in the balloon group and 3 in the control group, occurring in 13 participants. Fifteen of those serious events were device related, affecting 8 participants, or 3.0 percent of the treatment group.
Every one of those 15 device related serious adverse events followed placement of the second balloon. The FDA’s document states plainly that there were no serious adverse events reported for the first balloon. The events included gastric and esophageal ulcers and gastrointestinal bleeding, and one gastric perforation with tissue necrosis occurring one day after a second balloon placement, in a participant with an underlying clotting disorder.
There were no deaths and no small bowel obstructions. Ninety seven percent of all adverse events were mild or moderate.
Nausea, vomiting, and abdominal cramping in the first several days are close to universal with any liquid filled balloon while the stomach accommodates it. That is expected and it settles. The balloon number two finding is a different category of information, and any program recommending a second balloon should be raising it with you rather than waiting for you to find it.
What the four months are actually for
The balloon is designed to remain in the stomach for about 16 weeks. In the trial, the average was 15.3 weeks. A degradable valve in the balloon opens on schedule, the fluid empties, and the deflated shell passes through the intestine on its own.
Four months is not long enough to lose a lifetime of weight, and it is not supposed to be. What it is long enough for is to change what a normal portion feels like while you still have the physical feedback of a full stomach telling you when to stop. The program running alongside it is doing the durable work. The balloon is buying that program a window where compliance is much easier than it would be otherwise.
This is why I am cautious about anyone selling a balloon without a serious nutrition program attached. The trial’s control group, on the program alone, lost 3.09 percent. The program is not the free add on. It is roughly half the result.
Nothing altered, nothing absorbed
The reason patients ask about a balloon in the first place is usually that they want something reversible. The Allurion balloon does not cut, staple, or reroute anything, and it does not change absorption or introduce a drug into the body. It occupies space in the stomach for four months and then it leaves.
That makes it the least invasive option on the menu, and it also makes it the one with the smallest average result. Both of those are true at once, and choosing it is a reasonable trade for the right person.
Compare the balloon against a year on a GLP-1 using your own numbers
Which one costs less depends on what you would otherwise spend on medication over twelve months, and on whether you plan to stay on it past that.
Balloon versus a year of GLP-1
The comparison patients actually want is against what they would spend on medication.
A GLP-1 program is an ongoing monthly cost with no defined end, and the weight tends to return when it stops. A balloon program is a single defined cost with a defined end, and what happens after depends entirely on what the four months taught you.
Neither is universally the better buy. The balloon makes more sense for someone with a moderate amount to lose who wants a bounded commitment. Medication makes more sense for someone who needs a larger result or who has metabolic disease that the medication also treats. A number of patients end up doing both, in sequence.
Paying for it
Balloon programs are generally eligible for HSA and FSA funds. Those dollars are pre tax, so using them effectively discounts the program by your marginal tax rate, and it is the single most overlooked way to reduce what it actually costs you. Confirm with your plan administrator before you assume it.
Medical financing through third party lenders is widely available and is how most balloon patients pay. Compare the total amount repaid rather than the monthly payment, and check whether a promotional interest rate is deferred, meaning it accrues from day one and gets applied retroactively if the balance is not cleared inside the promotional window. At Karas Weight Loss that means CareCredit or Cherry financing, with monthly payment plans for the full balloon program price.
Any program should answer these in writing before it takes a deposit
A deposit collected before you have the full number in writing is how line items nobody mentioned up front show up later.
Easy monthly payments for the Allurion program
Insurance does not cover the balloon, so most patients finance it. Karas Weight Loss accepts CareCredit and Cherry, both with monthly payment plans and applications that take minutes.
What to ask before you pay a deposit
What is the total price, and what is specifically not in it.
Is removal included, and for a swallowed balloon, is there any removal cost at all.
How many months of nutrition and monitoring are included, and how many visits.
Who do I actually see at those visits.
Does the price assume one balloon or two, and what does a second one cost.
What happens if the balloon has to come out early.
Is the deposit refundable, and under what conditions.
Common questions
Does insurance cover a gastric balloon? Almost never. Balloons are typically classed as not medically necessary by commercial plans, which is why every practice quotes a cash price.
How much does the Allurion program cost? Prices differ substantially between practices, and promotional offers appear and disappear. Rather than compare headline numbers, ask each practice for one all inclusive figure in writing and confirm what it includes: the balloon, the placement, how many months of nutrition support, how many visits, and whether the number assumes one balloon or two. We give ours in writing at the consultation.
How much weight will I lose with the Allurion balloon? The randomized trial reported an average of 6.87 percent of total body weight at 48 weeks with the full protocol of up to two balloons, against 3.09 percent for the program alone. Individual results vary widely around that average, and about a third of trial participants did not complete the study.
Does the balloon need to be removed? Not for the Allurion. The valve opens at around 16 weeks, the balloon empties, and it passes on its own. Endoscopically placed balloons such as the Orbera do require a removal appointment.
Do I qualify? The approved indication is adults aged 22 to 65 with a BMI between 30 and 40 who have tried at least one structured weight loss program before. Many people who fall below the threshold for surgery fall inside this range.
How bad is the nausea? Nausea and vomiting in the first few days are expected with any liquid filled balloon and are managed with medication. Ninety seven percent of adverse events in the trial were mild or moderate.
Can I have a second balloon? The approved system allows for up to two within a 10 month period. Before agreeing to one, read the safety section above, because every device related serious adverse event in the pivotal trial followed the second placement.
Find out if the balloon fits you
The approved indication is narrow: adults 22 to 65, a BMI between 30 and 40, and at least one structured weight loss attempt behind you. Fifteen minutes in the office is enough to tell you whether that describes you and whether the program is worth your money.
Sources
U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data, Allurion Gastric Balloon System, PMA P250023.
U.S. Food and Drug Administration. Premarket Approval database, P250023.
Allurion Technologies. Allurion Receives U.S. FDA Approval. February 23, 2026.